<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2119259297-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2119259297-430x241.jpg"/></p>
<p>2025 年欧盟药品出口总值较 2024 年增长了 16%。图片来源：Alex Verrone / Shutterstock.com。</p>
<p>欧盟（EU）发布的新数据显示，2025 年该地区的 制药贸易 年同比价值显著上升——欧盟表示这些统计数据代表了其药品行业的创纪录贸易平衡。</p>
<p>2025 年，欧盟药品出口总值达 3662 亿欧元（4293 亿美元），较 2024 年欧盟制药贸易的 3157 亿欧元增长了 16%。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>希腊医疗（制药和医疗设备）市场分析，监管...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>比利时 - 医疗、监管和报销环境</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>尽管出口有所上升，2025 年欧盟药品进口支出也增长了 21%，各国在这一年花费了 1457 亿欧元购买药品。</p>
<p>这使得欧盟在 2025 年实现了 2205 亿欧元的贸易顺差，比 2024 年的 1953 亿欧元顺差大近 300 亿欧元。</p>
<p>根据 GlobalData 欧洲制药管理分析师 Eoin Ryan 的说法，考虑到与美国关税政策相关的地缘政治和经济不确定性，欧盟的贸易表现 “令人印象深刻”。</p>
<p>在比较欧盟各国的出口总值时，爱尔兰在同行中领先——通过其 938 亿欧元的贡献，带来了欧盟总制药贸易价值的四分之一以上。同时，德国和比利时分别位列第二和第三，两个国家的药品出口分别为 679 亿欧元和 385 亿欧元。</p>
<h2>美国仍然是欧盟的重要市场</h2>
<p>2025 年，美国是欧盟药品出口的主要目的地，44%（或 1606 亿欧元）的欧盟总药品出口流向美国市场。</p>
<p>然而，Ryan 指出，这些趋势可能是 “前置装运” 的迹象，因为美国进口商希望在特朗普政府的关税威胁面前保持领先。“已经有证据表明，2026 年第一季度欧盟对美国的药品贸易流动放缓，可能会局限于较弱的增长前景，” 他说。</p>
<p>对欧盟品牌药品进口美国征收的 15% 关税将对这一趋势产生影响，尽管没有达成协议的国家将很快面临 100% 的进口税。</p>
<p>尽管像欧洲制药工业和协会联合会（EFPIA）这样的贸易机构 表达了他们的担忧 关于欧盟 - 美国贸易协议的影响，但之前接受_制药技术_采访的专家表示，尽管关税动荡影响了欧盟的底线，欧洲与美国的制药贸易仍将至关重要。</p>
<h2>欧盟希望保持竞争力</h2>
<p>欧盟统计局发布的积极贸易顺差数据正值欧盟希望提升其制药行业在全球舞台上的竞争力之际，因为该国面临来自美国和中国的激烈竞争。</p>
<p>尽管专家们之前警告称，欧洲在与同行竞争方面的努力 未能达到预期，但欧洲实体现在正在采取行动改变这一局面。</p>
<p>2026 年 2 月，欧洲风险投资公司 联合成立 欧洲生命科学联盟（ELSC），以应对该大陆金融吸引力的下滑。在此之前一个月，诺和诺德基金会 投入了 8.5 亿美元 用于欧洲生命科学领域，原因类似。</p>
<p>尽管有这些努力，Ryan 警告称，中东的地缘政治事件可能对欧盟制药出口增长构成潜在制约，因为冲突可能 “扰乱重要的贸易走廊和全球供应链，超出能源行业”，这可能对欧盟制药公司产生重大影响。</p>
<p>然而，企业仍然在 与美国相比，押注于欧洲 进行合同药物生产（CM）。在 2025 年，美国经历了五年来 FDA 批准的药物在本土销售的 CM 交易最大降幅。与此同时，欧洲的交易保持稳定。</p>
<p>在与_《制药技术》_的 之前对话中，合同开发和生产组织（CDMOs）指出，欧洲仍然是一个具有吸引力的扩展地区，因为与美国相比，其生产成本较低，同时拥有严格的监管标准和丰富的人才基础设施。</p>

欧洲优质股利增长基金 - WisdomTree

欧洲 富时 ETF - Vanguard

欧洲核心 MSCI ETF - iShares

医疗业 3 倍做多 - Direxion

<p>欧盟的制药出口在 2025 年增长了 16%，总额达到 3662 亿欧元，创下 2205 亿欧元的贸易顺差。然而，分析师警告可能出现 “前置采购” 效应，预计由于美国关税和地缘政治不确定性，2026 年的增长将较弱。爱尔兰在欧盟出口中位居首位，其次是德国和比利时，美国占总出口的 44%。尽管面临挑战，欧盟仍旨在通过新举措和对该行业的投资来增强其在与美国和中国的制药竞争力</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2119259297-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2119259297-430x241.jpg"/></p>
<p>The total value of EU drug exports grew 16% in 2025 versus 2024. Credit: Alex Verrone / Shutterstock.com.</p>
<div class="lb-trans"><p>2025 年欧盟药品出口总值较 2024 年增长了 16%。图片来源：Alex Verrone / Shutterstock.com。</p>
</div><p>New figures debuted by the European Union (EU) have uncovered a significant rise in the year-on-year value of pharma trade seen across the region in 2025 – stats the EU says represent a record trade balance for its medicines sector.</p>
<div class="lb-trans"><p>欧盟（EU）发布的新数据显示，2025 年该地区的 制药贸易 年同比价值显著上升——欧盟表示这些统计数据代表了其药品行业的创纪录贸易平衡。</p>
</div><p>In 2025, the value of EU drug exports totalled €366.2bn ($429.3bn), marking a 16% rise from the €315.7bn the pharma trade across the union brought in during 2024.</p>
<div class="lb-trans"><p>2025 年，欧盟药品出口总值达 3662 亿欧元（4293 亿美元），较 2024 年欧盟制药贸易的 3157 亿欧元增长了 16%。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Greece Healthcare (Pharma and Medical Devices) Market Analysis, Reg...</h4>
<div class="lb-trans"><h4>希腊医疗（制药和医疗设备）市场分析，监管...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Belgium - Healthcare, Regulatory and Reimbursement Landscape</h4>
<div class="lb-trans"><h4>比利时 - 医疗、监管和报销环境</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>While exports took an uptick, the EU total drug import spend was also 21% higher in 2025, with countries across the political union forking out €145.7bn for medicines throughout the year.</p>
<div class="lb-trans"><p>尽管出口有所上升，2025 年欧盟药品进口支出也增长了 21%，各国在这一年花费了 1457 亿欧元购买药品。</p>
</div><p>This leaves the EU with a 2025 trade surplus of €220.5bn in 2025, nearly €30bn larger than the €195.3bn surplus in 2024.</p>
<div class="lb-trans"><p>这使得欧盟在 2025 年实现了 2205 亿欧元的贸易顺差，比 2024 年的 1953 亿欧元顺差大近 300 亿欧元。</p>
</div><p>According to Eoin Ryan, pharma managing analyst for Europe at GlobalData, the EU’s trade performance is “impressive”, considering it occurred against the backdrop of geopolitical and economic uncertainty linked to US tariff policies.</p>
<div class="lb-trans"><p>根据 GlobalData 欧洲制药管理分析师 Eoin Ryan 的说法，考虑到与美国关税政策相关的地缘政治和经济不确定性，欧盟的贸易表现 “令人印象深刻”。</p>
</div><p>When comparing the total value of ex-Europe exports across nations in the EU, Ireland took the helm over its peers – bringing in just over a quarter of the EU’s total pharma trade value through its €93.8bn contribution. Meanwhile, Germany and Belgium took second and third place, and medicines exports from each country raked in €67.9bn and €38.5bn, respectively, for the EU.</p>
<div class="lb-trans"><p>在比较欧盟各国的出口总值时，爱尔兰在同行中领先——通过其 938 亿欧元的贡献，带来了欧盟总制药贸易价值的四分之一以上。同时，德国和比利时分别位列第二和第三，两个国家的药品出口分别为 679 亿欧元和 385 亿欧元。</p>
</div><h2>US remains crucial market for EU</h2>
<div class="lb-trans"><h2>美国仍然是欧盟的重要市场</h2>
</div><p>In 2025, the US was the main destination for EU drug exports, with 44% (or €160.6bn) of the union’s total medicines exports heading to the US market.</p>
<div class="lb-trans"><p>2025 年，美国是欧盟药品出口的主要目的地，44%（或 1606 亿欧元）的欧盟总药品出口流向美国市场。</p>
</div><p>However, Ryan noted that these trends could be a sign of “frontloading”, as US importers looked to stay one step ahead of tariff threats posed by the Trump administration. “There is already evidence that the EU-to-US medicines trade flow slowed in Q1 2026 and is likely to be confined to a weaker growth outlook,” he said.</p>
<div class="lb-trans"><p>然而，Ryan 指出，这些趋势可能是 “前置装运” 的迹象，因为美国进口商希望在特朗普政府的关税威胁面前保持领先。“已经有证据表明，2026 年第一季度欧盟对美国的药品贸易流动放缓，可能会局限于较弱的增长前景，” 他说。</p>
</div><p>15% tariffs placed on the EU’s branded drug imports to the US will play a part in this trend, though nations without a deal will soon be subject to 100% import taxes.</p>
<div class="lb-trans"><p>对欧盟品牌药品进口美国征收的 15% 关税将对这一趋势产生影响，尽管没有达成协议的国家将很快面临 100% 的进口税。</p>
</div><p>While trade bodies like the European Federation of Pharmaceutical Industries and Associations (EFPIA) voiced their concerns on the implications of the EU-US trade deal, experts previously interviewed by <em>Pharmaceutical Technology</em> say that Europe’s pharma trade with the US will remain critical, despite tariff turmoil impacting the union’s bottom line.</p>
<div class="lb-trans"><p>尽管像欧洲制药工业和协会联合会（EFPIA）这样的贸易机构 表达了他们的担忧 关于欧盟 - 美国贸易协议的影响，但之前接受_制药技术_采访的专家表示，尽管关税动荡影响了欧盟的底线，欧洲与美国的制药贸易仍将至关重要。</p>
</div><h2>EU looks to retain competitiveness</h2>
<div class="lb-trans"><h2>欧盟希望保持竞争力</h2>
</div><p>The positive trade surplus figures posted by Eurostat come as the EU looks to boost the competitiveness of its pharma industry on the global stage, as the nation contends with heated rivalry from the US and China.</p>
<div class="lb-trans"><p>欧盟统计局发布的积极贸易顺差数据正值欧盟希望提升其制药行业在全球舞台上的竞争力之际，因为该国面临来自美国和中国的激烈竞争。</p>
</div><p>While experts have previously warned that Europe’s efforts to keep up with its peers are falling short, European entities are now taking action to shift this narrative.</p>
<div class="lb-trans"><p>尽管专家们之前警告称，欧洲在与同行竞争方面的努力 未能达到预期，但欧洲实体现在正在采取行动改变这一局面。</p>
</div><p>In February 2026, European venture capital firms created The European Life Sciences Coalition (ELSC) to tackle the slump in the continent’s financial attractiveness. A month before this, the Novo Nordisk Foundation poured $850m into the European life sciences sector for similar reasons.</p>
<div class="lb-trans"><p>2026 年 2 月，欧洲风险投资公司 联合成立 欧洲生命科学联盟（ELSC），以应对该大陆金融吸引力的下滑。在此之前一个月，诺和诺德基金会 投入了 8.5 亿美元 用于欧洲生命科学领域，原因类似。</p>
</div><p>Despite these efforts, Ryan warned that geopolitical events in the Middle East could pose a potential constraint to EU pharma export growth, as conflict could “disrupt vital trade corridors and global supply chains beyond the energy industry”, which could have significant implications for EU-based drugmakers.</p>
<div class="lb-trans"><p>尽管有这些努力，Ryan 警告称，中东的地缘政治事件可能对欧盟制药出口增长构成潜在制约，因为冲突可能 “扰乱重要的贸易走廊和全球供应链，超出能源行业”，这可能对欧盟制药公司产生重大影响。</p>
</div><p>However, companies are still betting on the continent over the US for contract drug manufacturing (CM). In 2025, the US experienced the largest drop in CM deals for FDA-approved drugs to be sold on home turf in half a decade. Meanwhile, deals across Europe remained consistent.</p>
<div class="lb-trans"><p>然而，企业仍然在 与美国相比，押注于欧洲 进行合同药物生产（CM）。在 2025 年，美国经历了五年来 FDA 批准的药物在本土销售的 CM 交易最大降幅。与此同时，欧洲的交易保持稳定。</p>
</div><p>In a previous conversation with Pharmaceutical Technology, contract development and manufacturing organisations (CDMOs) noted that Europe is still an attractive region for expansion due to its reduced production costs compared with the US, as well as its stringent regulatory standards and the talent infrastructure present on the continent.</p>
<div class="lb-trans"><p>在与_《制药技术》_的 之前对话中，合同开发和生产组织（CDMOs）指出，欧洲仍然是一个具有吸引力的扩展地区，因为与美国相比，其生产成本较低，同时拥有严格的监管标准和丰富的人才基础设施。</p>
</div>

尽管存在竞争力方面的担忧，欧盟预计 2025 年制药出口将有所增长